<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38138524</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1420-3049</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>24</Issue><PubDate><Year>2023</Year><Month>Dec</Month><Day>10</Day></PubDate></JournalIssue><Title>Molecules (Basel, Switzerland)</Title><ISOAbbreviation>Molecules</ISOAbbreviation></Journal><ArticleTitle>In Silico Screening of Natural Flavonoids against 3-Chymotrypsin-like Protease of SARS-CoV-2 Using Machine Learning and Molecular Modeling.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">8034</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/molecules28248034</ELocationID><Abstract><AbstractText>The "Long-COVID syndrome" has posed significant challenges due to a lack of validated therapeutic options. We developed a novel multi-step virtual screening strategy to reliably identify inhibitors against 3-chymotrypsin-like protease of SARS-CoV-2 from abundant flavonoids, which represents a promising source of antiviral and immune-boosting nutrients. We identified 57 interacting residues as contributors to the protein-ligand binding pocket. Their energy interaction profiles constituted the input features for Machine Learning (ML) models. The consensus of 25 classifiers trained using various ML algorithms attained 93.9% accuracy and a 6.4% false-positive-rate. The consensus of 10 regression models for binding energy prediction also achieved a low root-mean-square error of 1.18 kcal/mol. We screened out 120 flavonoid hits first and retained 50 drug-like hits after predefined ADMET filtering to ensure bioavailability and safety profiles. Furthermore, molecular dynamics simulations prioritized nine bioactive flavonoids as promising anti-SARS-CoV-2 agents exhibiting both high structural stability (root-mean-square deviation &lt; 5 &#xc5; for 218 ns) and low MM/PBSA binding free energy (&lt;-6 kcal/mol). Among them, KB-2 (PubChem-CID, 14630497) and 9-<i>O</i>-Methylglyceofuran (PubChem-CID, 44257401) displayed excellent binding affinity and desirable pharmacokinetic capabilities. These compounds have great potential to serve as oral nutraceuticals with therapeutic and prophylactic properties as care strategies for patients with long-COVID syndrome.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Lianjin</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-5354-4050</Identifier><AffiliationInfo><Affiliation>School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Fengyang</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-2775-9717</Identifier><AffiliationInfo><Affiliation>School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>Beihong</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Xibing</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0001-7431-7893</Identifier><AffiliationInfo><Affiliation>School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Luxuan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niu</LastName><ForeName>Taoyu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhai</LastName><ForeName>Jingchen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Junmei</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9607-8229</Identifier><AffiliationInfo><Affiliation>School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 GM147673</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM149705</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01GM147673</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01GM149705</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Molecules</MedlineTA><NlmUniqueID>100964009</NlmUniqueID><ISSNLinking>1420-3049</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.21.39</RegistryNumber><NameOfSubstance UI="D053818">Chymases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005419">Flavonoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053818" MajorTopicYN="N">Chymases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056004" MajorTopicYN="N">Molecular Dynamics Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005419" MajorTopicYN="N">Flavonoids</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="N">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">3-chyomotrypsin-like protease (3CL-pro)</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">flavonoids</Keyword><Keyword MajorTopicYN="N">ligand&#x2013;residue interaction profiles</Keyword><Keyword MajorTopicYN="N">long-COVID</Keyword><Keyword MajorTopicYN="N">machine learning-based scoring function (ML-based SF)</Keyword><Keyword MajorTopicYN="N">main protease (M-pro)</Keyword><Keyword MajorTopicYN="N">molecular dynamics simulation</Keyword><Keyword MajorTopicYN="N">molecular modeling</Keyword><Keyword MajorTopicYN="N">structure-based virtual screening (SBVS)</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>23</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>23</Day><Hour>1</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>12</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38138524</ArticleId><ArticleId IdType="pmc">PMC10745665</ArticleId><ArticleId IdType="doi">10.3390/molecules28248034</ArticleId><ArticleId IdType="pii">molecules28248034</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 2020;382:727&#x2013;733. doi: 10.1056/NEJMoa2001017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001017</ArticleId><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D., Saunders N., Maes P., Guivel-Benhassine F., Planchais C., Buchrieser J., Bolland W.-H., Porrot F., Staropoli I., Lemoine F., et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022;602:671&#x2013;675. doi: 10.1038/s41586-021-04389-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04389-z</ArticleId><ArticleId IdType="pubmed">35016199</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Rocklov J. The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus. J. Travel Med. 2021;28:taab124. doi: 10.1093/jtm/taab124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jtm/taab124</ArticleId><ArticleId IdType="pmc">PMC8436367</ArticleId><ArticleId IdType="pubmed">34369565</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasserie T., Hittle M., Goodman S.N. Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19. JAMA Netw. Open. 2021;4:e2111417. doi: 10.1001/jamanetworkopen.2021.11417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.11417</ArticleId><ArticleId IdType="pmc">PMC8155823</ArticleId><ArticleId IdType="pubmed">34037731</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T., Knight M., A&#x2019;Court C., Buxton M., Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026. doi: 10.1136/bmj.m3026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3026</ArticleId><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall M. The lasting misery of coronavirus long-haulers. Nature. 2020;585:339&#x2013;341. doi: 10.1038/d41586-020-02598-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-020-02598-6</ArticleId><ArticleId IdType="pubmed">32929257</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutchmansingh D.D., Higuero Sevilla J.P., Possick J.D., Gulati M. Long Haulers. Semin. Respir. Crit. Care Med. 2023;44:130&#x2013;142. doi: 10.1055/s-0042-1759568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0042-1759568</ArticleId><ArticleId IdType="pubmed">36646091</ArticleId></ArticleIdList></Reference><Reference><Citation>Catalano A., Iacopetta D., Ceramella J., Maio A.C.D., Basile G., Giuzio F., Bonomo M.G., Aquaro S., Walsh T.J., Sinicropi M.S., et al. Are Nutraceuticals Effective in COVID-19 and Post-COVID Prevention and Treatment? Foods. 2022;11:2884. doi: 10.3390/foods11182884.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/foods11182884</ArticleId><ArticleId IdType="pmc">PMC9498392</ArticleId><ArticleId IdType="pubmed">36141012</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023;21:133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Mody V., Ho J., Wills S., Mawri A., Lawson L., Ebert M.C.C.J.C., Fortin G.M., Rayalam S., Taval S. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents. Commun. Biol. 2021;4:93. doi: 10.1038/s42003-020-01577-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-020-01577-x</ArticleId><ArticleId IdType="pmc">PMC7817688</ArticleId><ArticleId IdType="pubmed">33473151</ArticleId></ArticleIdList></Reference><Reference><Citation>Needle D., Lountos G.T., Waugh D.S. Structures of the Middle East respiratory syndrome coronavirus 3C-like protease reveal insights into substrate specificity. Acta Crystallogr. Sect. D Biol. Crystallogr. 2015;71:1102&#x2013;1111. doi: 10.1107/S1399004715003521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S1399004715003521</ArticleId><ArticleId IdType="pmc">PMC4427198</ArticleId><ArticleId IdType="pubmed">25945576</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand K., Ziebuhr J., Wadhwani P., Mesters J.R., Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: Basis for design of anti-SARS drugs. Science. 2003;300:1763&#x2013;1767. doi: 10.1126/science.1085658.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1085658</ArticleId><ArticleId IdType="pubmed">12746549</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhary O.P., Dhawan M. Priyanka Omicron variant (B.1.1.529) of SARS-CoV-2: Threat assessment and plan of action. Int. J. Surg. 2022;97:106187. doi: 10.1016/j.ijsu.2021.106187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2021.106187</ArticleId><ArticleId IdType="pmc">PMC8656212</ArticleId><ArticleId IdType="pubmed">34896627</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouhar S.A., Elshahid Z.A. Molecular docking and simulation studies of synthetic protease inhibitors against COVID-19: A computational study. J. Biomol. Struct. Dyn. 2021;40:13976&#x2013;13996. doi: 10.1080/07391102.2021.1997822.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2021.1997822</ArticleId><ArticleId IdType="pubmed">34738871</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y.W., Yiu C.B., Wong K.Y. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure: Virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000Res. 2020;9:129. doi: 10.12688/f1000research.22457.2.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.22457.2</ArticleId><ArticleId IdType="pmc">PMC7062204</ArticleId><ArticleId IdType="pubmed">32194944</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z., Yang L., Zhang X., Zhang Q., Yang Z., Liu Y., Wei S., Liu W. Discovery of Potential Flavonoid Inhibitors Against COVID-19 3CL Proteinase Based on Virtual Screening Strategy. Front. Mol. Biosci. 2020;7:556481. doi: 10.3389/fmolb.2020.556481.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2020.556481</ArticleId><ArticleId IdType="pmc">PMC7561382</ArticleId><ArticleId IdType="pubmed">33134310</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuzikov M., Costanzi E., Reinshagen J., Esposito F., Vangeel L., Wolf M., Ellinger B., Claussen C., Geisslinger G., Corona A., et al. Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen. ACS Pharmacol. Transl. Sci. 2021;4:1096&#x2013;1110. doi: 10.1021/acsptsci.0c00216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsptsci.0c00216</ArticleId><ArticleId IdType="pmc">PMC7986981</ArticleId><ArticleId IdType="pubmed">35287429</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen D.R., Allerton C.M.N., Anderson A.S., Aschenbrenner L., Avery M., Berritt S., Boras B., Cardin R.D., Carlo A., Coffman K.J., et al. An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374:1586&#x2013;1593. doi: 10.1126/science.abl4784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abl4784</ArticleId><ArticleId IdType="pubmed">34726479</ArticleId></ArticleIdList></Reference><Reference><Citation>Wanounou M., Caraco Y., Levy R.H., Bialer M., Perucca E. Clinically Relevant Interactions Between Ritonavir-Boosted Nirmatrelvir and Concomitant Antiseizure Medications: Implications for the Management of COVID-19 in Patients with Epilepsy. Clin. Pharmacokinet. 2022;61:1219&#x2013;1236. doi: 10.1007/s40262-022-01152-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40262-022-01152-z</ArticleId><ArticleId IdType="pmc">PMC9325946</ArticleId><ArticleId IdType="pubmed">35895276</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drug Administration . Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid. FDA; White Oak, MD, USA: 2022.</Citation></Reference><Reference><Citation>EMA  EMA Issues Advice on Use of Paxlovid (PF-07321332 and Ritonavir) for the Treatment of COVID-19: Rolling Review Starts in Parallel.  [(accessed on 26 September 2023)].  Available online:  https://www.ema.europa.eu/en/news/ema-issues-advice-use-paxlovid-pf-07321332-ritonavir-treatment-covid-19-rolling-review-starts.</Citation></Reference><Reference><Citation>Bardel&#x10d;&#xed;kov&#xe1; A., Miro&#x161;&#x161;ay A., &#x160;olt&#xfd;s J., Moj&#x17e;i&#x161; J. Therapeutic and prophylactic effect of flavonoids in post-COVID-19 therapy. Phytother. Res. 2022;36:2042&#x2013;2060. doi: 10.1002/ptr.7436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ptr.7436</ArticleId><ArticleId IdType="pmc">PMC9111001</ArticleId><ArticleId IdType="pubmed">35302260</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzaabi M.M., Hamdy R., Ashmawy N.S., Hamoda A.M., Alkhayat F., Khademi N.N., Al Joud S.M.A., El-Keblawy A.A., Soliman S.S.M. Flavonoids are promising safe therapy against COVID-19. Phytochem. Rev. 2022;21:291&#x2013;312. doi: 10.1007/s11101-021-09759-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11101-021-09759-z</ArticleId><ArticleId IdType="pmc">PMC8139868</ArticleId><ArticleId IdType="pubmed">34054380</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhuiyan F.R., Howlader S., Raihan T., Hasan M. Plants Metabolites: Possibility of Natural Therapeutics Against the COVID-19 Pandemic. Front. Med. 2020;7:444. doi: 10.3389/fmed.2020.00444.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.00444</ArticleId><ArticleId IdType="pmc">PMC7427128</ArticleId><ArticleId IdType="pubmed">32850918</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo S., Kim S., Kim D.Y., Kim M.-S., Shin D.H. Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro. J. Enzym. Inhib. Med. Chem. 2020;35:1539&#x2013;1544. doi: 10.1080/14756366.2020.1801672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14756366.2020.1801672</ArticleId><ArticleId IdType="pmc">PMC7470085</ArticleId><ArticleId IdType="pubmed">32746637</ArticleId></ArticleIdList></Reference><Reference><Citation>Germano C., Messina A., Tavella E., Vitale R., Avellis V., Barboni M., Attini R., Revelli A., Zola P., Manzoni P., et al. Fetal Brain Damage during Maternal COVID-19: Emerging Hypothesis, Mechanism, and Possible Mitigation through Maternal-Targeted Nutritional Supplementation. Nutrients. 2022;14:3303. doi: 10.3390/nu14163303.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu14163303</ArticleId><ArticleId IdType="pmc">PMC9414753</ArticleId><ArticleId IdType="pubmed">36014809</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastor N., Collado M.C., Manzoni P. Phytonutrient and Nutraceutical Action against COVID-19: Current Review of Characteristics and Benefits. Nutrients. 2021;13:464. doi: 10.3390/nu13020464.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13020464</ArticleId><ArticleId IdType="pmc">PMC7910826</ArticleId><ArticleId IdType="pubmed">33573173</ArticleId></ArticleIdList></Reference><Reference><Citation>Sliwoski G., Kothiwale S., Meiler J., Lowe E.W. Computational Methods in Drug Discovery. Pharmacol. Rev. 2014;66:334&#x2013;395. doi: 10.1124/pr.112.007336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/pr.112.007336</ArticleId><ArticleId IdType="pmc">PMC3880464</ArticleId><ArticleId IdType="pubmed">24381236</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Su M., Liu Z., Li J., Liu J., Han L., Wang R. Assessing protein&#x2013;ligand interaction scoring functions with the CASF-2013 benchmark. Nat. Protoc. 2018;13:666&#x2013;680. doi: 10.1038/nprot.2017.114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2017.114</ArticleId><ArticleId IdType="pubmed">29517771</ArticleId></ArticleIdList></Reference><Reference><Citation>Leach A.R., Shoichet B.K., Peishoff C.E. Prediction of Protein&#x2212;Ligand Interactions. Docking and Scoring:&#x2009; Successes and Gaps. J. Med. Chem. 2006;49:5851&#x2013;5855. doi: 10.1021/jm060999m.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm060999m</ArticleId><ArticleId IdType="pubmed">17004700</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedes I.A., Pereira F.S.S., Dardenne L.E. Empirical Scoring Functions for Structure-Based Virtual Screening: Applications, Critical Aspects, and Challenges. Front. Pharmacol. 2018;9:1089. doi: 10.3389/fphar.2018.01089.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2018.01089</ArticleId><ArticleId IdType="pmc">PMC6165880</ArticleId><ArticleId IdType="pubmed">30319422</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji B., He X., Zhai J., Zhang Y., Man V.H., Wang J. Machine learning on ligand-residue interaction profiles to significantly improve binding affinity prediction. Brief. Bioinform. 2021;22:bbab054. doi: 10.1093/bib/bbab054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bbab054</ArticleId><ArticleId IdType="pmc">PMC8425425</ArticleId><ArticleId IdType="pubmed">33758923</ArticleId></ArticleIdList></Reference><Reference><Citation>Rifaioglu A.S., Atas H., Martin M.J., Cetin-Atalay R., Atalay V., Do&#x11f;an T. Recent applications of deep learning and machine intelligence on in silico drug discovery: Methods, tools and databases. Brief. Bioinform. 2018;20:1878&#x2013;1912. doi: 10.1093/bib/bby061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bby061</ArticleId><ArticleId IdType="pmc">PMC6917215</ArticleId><ArticleId IdType="pubmed">30084866</ArticleId></ArticleIdList></Reference><Reference><Citation>He C., Zhang C., Bian T., Jiao K., Su W., Wu K.-J., Su A. A Review on Artificial Intelligence Enabled Design, Synthesis, and Process Optimization of Chemical Products for Industry 4.0. Processes. 2023;11:330. doi: 10.3390/pr11020330.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pr11020330</ArticleId></ArticleIdList></Reference><Reference><Citation>Khamis M.A., Gomaa W. Comparative assessment of machine-learning scoring functions on PDBbind 2013. Eng. Appl. Artif. Intell. 2015;45:136&#x2013;151. doi: 10.1016/j.engappai.2015.06.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.engappai.2015.06.021</ArticleId></ArticleIdList></Reference><Reference><Citation>Crampon K., Giorkallos A., Deldossi M., Baud S., Steffenel L.A. Machine-learning methods for ligand-protein molecular docking. Drug Discov. Today. 2022;27:151&#x2013;164. doi: 10.1016/j.drudis.2021.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2021.09.007</ArticleId><ArticleId IdType="pubmed">34560276</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C., Chen E.A., Zhang Y. Protein&#x2013;Ligand Docking in the Machine-Learning Era. Molecules. 2022;27:4568. doi: 10.3390/molecules27144568.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27144568</ArticleId><ArticleId IdType="pmc">PMC9323102</ArticleId><ArticleId IdType="pubmed">35889440</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez D., Gaulton A., Bento A.P., Chambers J., De Veij M., F&#xe9;lix E., Magari&#xf1;os M.P., Mosquera J.F., Mutowo P., Nowotka M., et al. ChEMBL: Towards direct deposition of bioassay data. Nucleic Acids Res. 2018;47:D930&#x2013;D940. doi: 10.1093/nar/gky1075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky1075</ArticleId><ArticleId IdType="pmc">PMC6323927</ArticleId><ArticleId IdType="pubmed">30398643</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Suwa K. Search extension transforms Wiki into a relational system: A case for flavonoid metabolite database. BioData Min. 2008;1:7. doi: 10.1186/1756-0381-1-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1756-0381-1-7</ArticleId><ArticleId IdType="pmc">PMC2556319</ArticleId><ArticleId IdType="pubmed">18822113</ArticleId></ArticleIdList></Reference><Reference><Citation>Haibo H., Garcia E.A. Learning from Imbalanced Data. IEEE Trans. Knowl. Data Eng. 2009;21:1263&#x2013;1284. doi: 10.1109/TKDE.2008.239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/TKDE.2008.239</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss G.M., Provost F. Learning When Training Data are Costly: The Effect of Class Distribution on Tree Induction. J. Artif. Intell. Res. 2003;19:315&#x2013;354. doi: 10.1613/jair.1199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1613/jair.1199</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee A., Su A., Rajan K. Deep Learning Model for Identifying Critical Structural Motifs in Potential Endocrine Disruptors. J. Chem. Inf. Model. 2021;61:2187&#x2013;2197. doi: 10.1021/acs.jcim.0c01409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jcim.0c01409</ArticleId><ArticleId IdType="pubmed">33872000</ArticleId></ArticleIdList></Reference><Reference><Citation>Prentis R., Lis Y., Walker S. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964&#x2013;1985) Br. J. Clin. Pharmacol. 1988;25:387&#x2013;396. doi: 10.1111/j.1365-2125.1988.tb03318.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2125.1988.tb03318.x</ArticleId><ArticleId IdType="pmc">PMC1386364</ArticleId><ArticleId IdType="pubmed">3358900</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy T. Managing the drug discovery/development interface. Drug Discov. Today. 1997;2:436&#x2013;444. doi: 10.1016/S1359-6446(97)01099-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1359-6446(97)01099-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 2004;3:711&#x2013;716. doi: 10.1038/nrd1470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd1470</ArticleId><ArticleId IdType="pubmed">15286737</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Ma C., Wipf P., Liu H., Su W., Xie X.Q. TargetHunter: An in silico target identification tool for predicting therapeutic potential of small organic molecules based on chemogenomic database. AAPS J. 2013;15:395&#x2013;406. doi: 10.1208/s12248-012-9449-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12248-012-9449-z</ArticleId><ArticleId IdType="pmc">PMC3675739</ArticleId><ArticleId IdType="pubmed">23292636</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand P., Singh B. Flavonoids as lead compounds modulating the enzyme targets in Alzheimer&#x2019;s disease. Med. Chem. Res. 2013;22:3061&#x2013;3075. doi: 10.1007/s00044-012-0353-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00044-012-0353-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y., Zhang P., Yu H., Li J., Wang M.-W., Zhao W. Anti-Helicobacter pylori and Thrombin Inhibitory Components from Chinese Dragon&#x2019;s Blood, Dracaena cochinchinensis. J. Nat. Prod. 2007;70:1570&#x2013;1577. doi: 10.1021/np070260v.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/np070260v</ArticleId><ArticleId IdType="pubmed">17883259</ArticleId></ArticleIdList></Reference><Reference><Citation>Moro S., van Rhee A.M., Sanders L.H., Jacobson K.A. Flavonoid Derivatives as Adenosine Receptor Antagonists:&#x2009; A Comparison of the Hypothetical Receptor Binding Site Based on a Comparative Molecular Field Analysis Model. J. Med. Chem. 1998;41:46&#x2013;52. doi: 10.1021/jm970446z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm970446z</ArticleId><ArticleId IdType="pmc">PMC10802111</ArticleId><ArticleId IdType="pubmed">9438021</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumari M., Subbarao N. Deep learning model for virtual screening of novel 3C-like protease enzyme inhibitors against SARS coronavirus diseases. Comput. Biol. Med. 2021;132:104317. doi: 10.1016/j.compbiomed.2021.104317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.compbiomed.2021.104317</ArticleId><ArticleId IdType="pmc">PMC7935676</ArticleId><ArticleId IdType="pubmed">33721736</ArticleId></ArticleIdList></Reference><Reference><Citation>Case D.A., Belfon K., Ben-Shalom I.Y., Berryman J.T., Brozell S.R., Cerutti D.S., Cheatham T.E., III, Cisneros G.A., Cruzeiro V.W.D., Darden T.A., et al. Amber 2022. University of California; San Francisco, CA, USA: 2022.</Citation></Reference><Reference><Citation>Das S.K., Chen S., Deasy J.O., Zhou S., Yin F.-F., Marks L.B. Combining multiple models to generate consensus: Application to radiation-induced pneumonitis prediction. Med. Phys. 2008;35:5098&#x2013;5109. doi: 10.1118/1.2996012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1118/1.2996012</ArticleId><ArticleId IdType="pmc">PMC2673598</ArticleId><ArticleId IdType="pubmed">19070244</ArticleId></ArticleIdList></Reference><Reference><Citation>Friesner R.A., Banks J.L., Murphy R.B., Halgren T.A., Klicic J.J., Mainz D.T., Repasky M.P., Knoll E.H., Shelley M., Perry J.K., et al. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 2004;47:1739&#x2013;1749. doi: 10.1021/jm0306430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm0306430</ArticleId><ArticleId IdType="pubmed">15027865</ArticleId></ArticleIdList></Reference><Reference><Citation>Halgren T.A., Murphy R.B., Friesner R.A., Beard H.S., Frye L.L., Pollard W.T., Banks J.L. Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem. 2004;47:1750&#x2013;1759. doi: 10.1021/jm030644s.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm030644s</ArticleId><ArticleId IdType="pubmed">15027866</ArticleId></ArticleIdList></Reference><Reference><Citation>Friesner R.A., Murphy R.B., Repasky M.P., Frye L.L., Greenwood J.R., Halgren T.A., Sanschagrin P.C., Mainz D.T. Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem. 2006;49:6177&#x2013;6196. doi: 10.1021/jm051256o.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm051256o</ArticleId><ArticleId IdType="pubmed">17034125</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorgensen W.L., Chandrasekhar J., Madura J.D., Impey R.W., Klein M.L. Comparison of Simple Potential Functions for Simulating Liquid Water. J. Chem. Phys. 1983;79:926&#x2013;935. doi: 10.1063/1.445869.</Citation><ArticleIdList><ArticleId IdType="doi">10.1063/1.445869</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Wang W., Kollman P.A., Case D.A. Automatic atom type and bond type perception in molecular mechanical calculations. J. Mol. Graph. Model. 2006;25:247&#x2013;260. doi: 10.1016/j.jmgm.2005.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmgm.2005.12.005</ArticleId><ArticleId IdType="pubmed">16458552</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayly C.I., Cieplak P., Cornell W.D., Kollman P.A. A Well-Behaved Electrostatic Potential Based Method Using Charge Restraints for Deriving Atomic Charges: The Resp Model. J. Phys. Chem. 1993;97:10269&#x2013;10280. doi: 10.1021/j100142a004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/j100142a004</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocchia W., Alexov E., Honig B. Extending the applicability of the nonlinear Poisson-Boltzmann equation: Multiple dielectric constants and multivalent ions. J. Phys. Chem. B. 2001;105:6507&#x2013;6514. doi: 10.1021/jp010454y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jp010454y</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Li C.A., Sarkar S., Zhang J., Witham S., Zhang Z., Wang L., Smith N., Petukh M., Alexov E. DelPhi: A comprehensive suite for DelPhi software and associated resources. BMC Biophys. 2012;5:9. doi: 10.1186/2046-1682-5-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2046-1682-5-9</ArticleId><ArticleId IdType="pmc">PMC3463482</ArticleId><ArticleId IdType="pubmed">22583952</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang E.C., Sun H.Y., Wang J.M., Wang Z., Liu H., Zhang J.Z.H., Hou T.J. End-Point Binding Free Energy Calculation with MM/PBSA and MM/GBSA: Strategies and Applications in Drug Design. Chem. Rev. 2019;119:9478&#x2013;9508. doi: 10.1021/acs.chemrev.9b00055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.chemrev.9b00055</ArticleId><ArticleId IdType="pubmed">31244000</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Hou T., Xu X. Recent Advances in Free Energy Calculations with a Combination of Molecular Mechanics and Continuum Models. Curr. Comput. Aided-Drug Des. 2006;2:287&#x2013;306. doi: 10.2174/157340906778226454.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/157340906778226454</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>